FDA Unveils Guidance for Biosimilar Development
After months of anticipation, the Food and Drug Administration issued guidances last month that outlines its recommendations for developing and approving biosimilar therapies. The announcement came the same day that FDA officials discussed new user fees for biosimilars and generic drugs at a Congressional hearing. Three separate draft guidances map out the scientific considerations, quality analytical factors and other regulatory issues for bringing to market new therapeutic proteins that are similar, “but not the same” as a reference product.
The documents describe a step-wise approval pathway, starting with extensive analytical, physico-chemical and biological characterization data that can demonstrate a high degree of similarity. FDA will evaluate that data and then provide advice to the sponsor on the extent and scope of animal and human testing needed to show biosimilarity. FDA will consider multiple factors in making study determinations, including product complexity, formulation, stability, structure-function relationships, manufacturing process and clinical experience with the reference product.
Unlike European regulators, FDA decided not to issue guidances for developing biosimilars in different drug product classes. If a specific issue arises with a specific class, we may write guidance, explained Rachel Sherman, director of the Office of Medical Policy in FDA’s Center for Drug Evaluation and Research. But so far, she said at a press briefing, “this has not been seen at the most efficient route.”
To avoid redundant and unnecessary animal and clinical testing, FDA will permit sponsors to use a non-US licensed comparator in certain studies, with appropriate bridging data. Most applications, though, will require some additional clinical trials, and Sherman expects that all will need immunogenicity studies.
Once FDA determines that a product is biosimilar, the sponsor can opt to demonstrate interchangeability. That will require additional switching studies to show that changing to the new product does not affect safety and efficacy. Interchangeability is a separate determination, and it’s sequential, Sherman emphasized. “It would not look like the generic drug model at all.”
FDA expects to be inundated with comments of these proposals and plans a public meeting to hear from stakeholders. Meanwhile, staffers are holding dozens of pre-IND meetings with sponsors and encouraging all prospective biosimilar makers to seek early advice. Nine INDs for biosimilar have been filed so far, and the agency is anticipating a full 351(k) application soon.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
